Jefferies' Aveo Pharmaceuticals Management Remains Confident in Differentiation From Inlyta

Comments
Loading...
Jefferies published a research report concerning Aveo Pharmaceuticals AVEO recent management meeting. In the report, Jefferies states, “We had the opportunity to meet with AVEO management for an update on their thoughts post-release of top-line TIVO-1 results. We continue to believe that the 12-month progression free survival (PFS) and superior side effect profile will make tivo the new standard of care for renal cell carcinoma (RCC).” Jefferies maintains its Buy rating and $30 PT on Aveo Pharmaceuticals, which closed Friday at $14.83.
PFS Logo
PFSProvident Financial Services Inc
$17.152.94%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum70.65
Growth83.60
Quality36.81
Value-
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: